Daily Stock List
Orgenesis, Inc. (ORGS)
Stock News Now, Streetwise Reports, Greenbackers, and SmallCapNetwork reported earlier on Orgenesis, Inc. (ORGS), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Orgenesis, Inc. is a fully-integrated biopharmaceutical company listed on the OTCQB. It has a novel therapeutic technology for the treatment of diabetes. Additionally, it has a fully-owned subsidiary contract manufacturing and development company - MaSTherCell. This subsidiary’s commitment is to cell therapy for advanced medicinal products. Orgenesis is headquartered in Germantown, Maryland.
Orgenesis has expertise and unique experience in cell therapy development and manufacturing. As well, via its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).
Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company utilizes a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
The basis of Orgenesis’ technology is on Intellectual Property (IP) licensed from Israel’s recognized Sheba Medical Center. The foundation of the portfolio is on the pioneering work and two decades of research by the acclaimed researcher, Prof. Sarah Ferber.
Orgenesis has demonstrated promising results in in-vitro and in-vivo studies using human liver tissues. It has designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.
Orgenesis Ltd., the wholly-owned subsidiary of Orgenesis, Inc., and South Korea-based CureCell Co. Ltd. were awarded a collaborative grant from the Korea-Israel Industrial R&D Foundation (KORIL-RDF) to finance their current co-development program. The program will include pre-clinical and clinical activities related to commercialization of the Orgenesis Autologous Insulin Producing (AIP) Cells for the treatment of diabetes.
Orgenesis, Inc. (ORGS), closed Wednesday's trading session at $0.41, even for the day, on 14 volume with 1 trade. The average volume for the last 60 days is 6,658 and the stock's 52-week low/high is $0.2352/$0.515.
STG Group, Inc. (STGG)
We are reporting on STG Group, Inc. (STGG) today, here at the QualityStocks Daily Newsletter.
OTCQB-listed, STG Group, Inc. is a foremost provider of mission-critical technology, cyber, and data solutions to the U.S. Government. The Company works to ensure the security of the digital domain, the effectiveness of complex Information Technology (IT) systems, and the delivery of quality intelligence to decision makers. STG was one of the first small companies to receive an ISO 9001:2008 certification and an SEI CMMI Maturity Level 3 rating. The Company serves its customers at more than 250 locations domestically and internationally. STG Group is headquartered in Reston, Virginia. It has offices in North Charleston, South Carolina, and Sierra Vista, Arizona.
STG provides performance-oriented solutions in cyber security and secure information systems, software development, systems and services and intelligence and analytics. The Company has expanded its core competencies. Some of its key projects have included engineering solutions for rapid prototyping and battlefield support, development of unique name searching algorithms for six language families, and niche scientific solutions for specialized agency missions.
STG solutions are essential to national security-related programs and day-to-day operations across greater than 50 U.S. government agencies. Regarding Cyber Security and Secure Information Systems, the Company’s mission is to establish, develop, and sustain secure, resilient, enterprise level information systems.
Concerning Software Development, Systems and Services, its agile software development practices scale to system demands. This ranges from iterative system builds to highly integrated enterprise platforms. Pertaining to Intelligence and Analytics, STG’s experts gather data from numerous sources, analyze and fuse the data to provide clarity and situational context, and disseminate the resulting intelligence to a varied range of stakeholders.
This past July, STG Group announced that it was awarded an ISO/IEC 27001:2013 Management System certificate for its Integrated Managed Operations, Solutions, and Intelligent Collaboration (MOSaIC Information Technology) and Information Security and Service Management Systems (ISSMS). The certificate applies to the management and control of the provision of Information Security (IS), Infrastructure and Operations, and IT Services to Global Enterprise business activities.
Recently, STG Group announced that Mr. William (Bill) Scott, Brigadier General, USA (Retired) has joined STG as Vice President Cyber Security and Secure Information Systems. In this role, Mr. Scott will work in partnership with the Sector General Manager and STG senior leadership in its efforts to establish and execute Sector growth strategies, manage STG resources, and develop pioneering solutions to secure highly sensitive, mission-critical national security networks. Mr. Scott has over two decades of operational and executive experience in government and industry, providing world-class automation and communications systems.
STG Group, Inc. (STGG), closed Wednesday's trading session at $2.50, down 9.09%, on 100 volume with 1 trade. The average volume for the last 60 days is 726 and the stock's 52-week low/high is $0.90/$16.98.
MetaStat, Inc. (MTST)
Innovative Marketing, The MicrocapNews, Goldman Small Cap Research, StocksImpossible, Club Penny Stocks Network, Pumps and Dumps, OTCBB Journal, and First Penny Picks reported earlier on MetaStat, Inc. (MTST), and today we report on the Company, here at the QualityStocks Daily Newsletter.
MetaStat, Inc. is a molecular diagnostic company that develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis - the process through which cancer spreads from a primary tumor via the bloodstream to other areas of the body. A life sciences enterprise, the Company’s focus is on breast, prostate, lung, and colorectal cancers, where systemic metastasis is responsible for approximately 90 percent of all deaths. MetaStat has its corporate headquarters in Boston, Massachusetts.
The foundation of MetaStat’s function-based diagnostic platform technology is on the identification and understanding of the vital role of the mena protein and its isoforms (a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors). The design of the MetaSite Breast™ and MenaCalc™ product lines are to accurately stratify patients based on their individual risk of metastasis and to enable clinicians to better customize cancer treatment decisions through positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy.
The MetaSite Breast™ test measures the process of systemic metastasis. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is widely applicable in solid epithelial-based cancers. The intention of the MetaSite Breast™ test is for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive (1-3), estrogen receptor-positive, HER2-negative disease.
MetaStat announced in January of this year the successful completion of an analytical validation study of its MenaCalc™ clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation (%CV) of only 2.3 percent (Range 0.07-6.95). The MenaCalc™ results were reported as a MenaCalc™ Score. The MenaCalc™ results better inform physicians in making treatment decisions to improve outcomes. The CLIA validated MenaCalc™ Diagnostic Test for the prediction of cancer metastasis is to be run at MetaStat’s CLIA Certified commercial laboratory.
MetaStat will present clinical data and results from two studies at the San Antonio Breast Cancer Symposium (SABCS), taking place December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
Mr. Douglas A. Hamilton, MetaStat Chief Executive Officer and President, stated, “We are pleased to have two of our studies involving MetaSite Breast™ accepted for presentation at this year’s San Antonio Breast Cancer Symposium, including an oral presentation by Dr. Joseph Sparano, principal investigator for the ECOG 2197 study.”
MetaStat, Inc. (MTST), closed Wednesday's trading session at $3.00, down 6.25%, on 816 volume with 3 trades. The average volume for the last 60 days is 969 and the stock's 52-week low/high is $1.00/$6.35.
AntriaBio, Inc. (ANTB)
BUYINS.NET, Ceocast News, and PennyStocks24 reported on AntriaBio, Inc. (ANTB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
AntriaBio, Inc. is a biopharmaceutical company centering on developing novel extended release therapies. It develops novel extended release therapies through combining proprietary formulation and manufacturing capabilities with well-known molecules to substantially improve standards of care. The Company develops inventive approaches to fulfill unmet clinical needs through applying its formulation capabilities to improve existing therapies. AntriaBio is based in Louisville, Colorado.
AntriaBio’s lead product candidate is AB101. This is an injectable once-weekly basal insulin for type 1 and type 2 diabetes. AB101 addresses a $10 billion market where the present standard of care is a once-daily basal insulin injection. AB101 is formulated from human recombinant insulin. This is different from existing basal insulin replacement therapies that use synthetic insulin analogues.
AB101 is now in preclinical development. It is to be administered by subcutaneous injection. The design of the formulation is to release human insulin slowly and uniformly over a period of about one week without an adverse initial burst of insulin. AntriaBio successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101. The studies assessed the receptor pharmacology, pharmacokinetics, and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients.
AntriaBio has another product candidate in its product development pipeline – AB301. As a potential treatment for patients with type 2 diabetes, AB301 is a weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's basal insulin lead product candidate.
In June 2016, AntriaBio announced that it released preclinical results in a diabetes animal model for its lead product candidate, AB101, at the American Diabetes Association 76th Scientific Sessions® in New Orleans, Louisiana. The study was conducted in Alloxan-induced diabetic mini-pigs whose glucose was not controlled on an existing insulin regimen. Results demonstrated that a single subcutaneous dose of AB101 produced a slow onset and sustained PK-PD effect over the duration of one week, with near normalization of glucose, a reduction in glycemic variability and a reduction followed by discontinuation of background insulin use.
Recently, AntriaBio announced that it is forming a new wholly-owned subsidiary in Seoul, South Korea. This subsidiary will concentrate on research and development and also potential manufacturing opportunities. AntriaBio’s intention is to simultaneously start raising capital mainly from Korean institutional investors with the aim of closing the financing before the end of this year. The additional capital will be used to fund AntriaBio’s initial clinical study in the U.S. for its lead product candidate, AB101, as well as operations through 2018.
AntriaBio, Inc. (ANTB), closed Wednesday's trading session at $1.23, down 3.15%, on 100 volume with 1 trade. The average volume for the last 60 days is 10,812 and the stock's 52-week low/high is $0.80/$2.00.
bBooth, Inc. (BBTH)
Cannabis Financial Network News reported earlier on bBooth, Inc. (BBTH), and we report on the Company today, here at the QualityStocks Daily Newsletter.
An entertainment technology company, bBooth, Inc. is connecting Hollywood to hometowns through placing professional-quality recording studios in local malls. The Company manufactures and operates Internet connected, broadcast-quality portable recording studios in the United States. It operates and markets its studios under the ‘bBooth’ brand. The Company previously went by the name Cutaia Media Group, LLC. It changed its name to bBooth, Inc. in May of 2014. Founded in 2012, bBooth is headquartered in West Hollywood, California.
Basically, bBooth is the junction between entertainment, social media and technology. It provides new opportunities for rising talent to engage with Hollywood auditions, events and ‘insider’ content. The Company’s booths accommodate different types of talent. This includes singers, actors, comedians, models, hosts, personalities, newscasters, bands, songwriters, and anyone wishing to express themselves and/or be discovered.
bBooth’s bNotifi technology is a push-to-screen, interactive, audio/video messaging and communications application. It is for industry leading social engagement on mobile/desktop/web platforms. bNotifi push-to-screen technology brings a person or product to life directly on the screens of fans' computers, tablets and mobile devices globally.
Concerning the bBooth Recording Studios, the Company is deploying kiosk-sized, family-friendly, professional-quality, TV recording studios in local shopping centers nationwide. Performances in bBooth are seen and heard on huge exterior monitors. Performances are also seen on the Company’s app and shared across social media platforms. Essentially, bBooth is a life-size, ‘SmartPhone’ style, interactive recording kiosk.
Some features of bBooth Recording Studios kiosks include a life-size interactive touchscreen display; an integrated HD camera that records high-quality video and stills; pro-quality, uni-directional mic minimized background noise; optional choice of karaoke songs with on-screen lyrics, and also custom branding options.
Last month, bBooth announced that it entered into an agreement with The Matrix Group (Torrance, California) to provide a push-to-screen, media-rich, interactive audio/video messaging and communications platform for enterprise-scale lead-generation, customer-retention, and training for The Matrix Group and 890,000 independent representatives in affiliate organizations. The Matrix Group is a collective body of entrepreneurs, business owners, doctors, attorneys, real estate agents, pastors, educators, entertainers, and more.
Mr. Rory J. Cutaia, bBooth’s Chief Executive Officer, stated, "We're very excited to work with Byron Nelson, the forward thinking Founder and CEO of The Matrix Group, to provide their independent representatives with the unrivaled power of our bNotifi technology."
bBooth, Inc. (BBTH), closed Wednesday's trading session at $0.12, up 20.00%, on 40,600 volume with 11 trades. The average volume for the last 60 days is 77,665 and the stock's 52-week low/high is $0.025/$1.50.
Agora Holdings, Inc. (AGHI)
The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.1599, up 10.28%, on 177,251 volume with 61 trades. The stock’s average daily volume over the past 60 days is 516,151, and its 52-week low/high is $0.01/$0.50.
Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.
Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.
For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.
Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.
Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer
Agora Holdings, Inc. Company Blog
Agora Holdings, Inc. News:
Agora Holdings, Inc. Issues Corporate Update on Current, Future Endeavors
Agora Holdings, Inc. Launches FRAME Social Media App
Agora Holdings Inc. Audit Is Complete, Company Continuing to Progress Its Plans to Move Up the Board to QB Level
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.009, up 4.65%, on 267,237 volume with 14 trades. The stock’s average daily volume over the past 60 days is 793,124, and its 52-week low/high is $0.0046/$0.018.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
Singlepoint, Inc. (SING) CEO Updates Shareholders in Interview on @MoneyTV with Donald Baillargeon
SinglePoint, Inc. Provides Update on Corporate Audit and Advancement to OTCQB
Singlepoint, Inc. (SING) to be Featured on MoneyTV with Donald Baillargeon, 9/16
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0013, even for the day, on 17,569,336 volume with 37 trades. The stock’s average daily volume over the past 60 days is 21,419,648 and its 52-week low/high is $0.001/$0.143.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Advances Its Plans for Africa
Dominovas Energy Petitions for Project Grants Through United States Trade and Development Agency
Dominovas Energy Seeks to Become an Exclusive Energy Provider for the University of Johannesburg
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.80, even for the day, on 15,169 volume with 33 trades. The stock’s average daily volume over the past 60 days is 7,923, and its 52-week low/high is $1.10/$5.00.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Monaker Groups Alternative Lodging Vacation Rentals Gain Exposure to Decision Makers at Over One Million Companies Worldwide
Monaker Group Achieves Key Milestone - Application Program Interface (API) and Booking Engine Complete
Monaker Launches Premium Service for Alternative Lodging Listings
OurPet's Company (OPCO)
The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.81, even for the day. The stock’s average daily volume over the past 60 days is 5,211, and its 52-week low/high is $0.67/$1.06.
OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.
In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.
The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.
OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer
OurPet's Company Company Blog
OurPet's Company News:
OurPet's Company CFO to Present at the MicroCap Conference in Philadelphia
Kathleen Homyock of OurPet's Company Presents Smart Technology Trends to Canadian Pet Industry
OurPet's Company to Present at The MicroCap Conference on October 24-25 in Philadelphia
Today's Top 3
The QualityStocks Public Company Sponsor News